In the latest trading session, Novavax (NVAX) closed at $8.42, marking a -5.5% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.38%. Meanwhile, the Dow experienced a rise of 0.02%, and the technology-dominated Nasdaq saw an increase of 0.9%.
Shares of the vaccine maker witnessed a loss of 3.26% over the previous month, trailing the performance of the Medical sector with its gain of 4.34%, and the S&P 500's gain of 1.27%.
The investment community will be closely monitoring the performance of Novavax in its forthcoming earnings report. On that day, Novavax is projected to report earnings of -$0.36 per share, which would represent a year-over-year decline of 158.06%. Meanwhile, our latest consensus estimate is calling for revenue of $50.04 million, down 79.08% from the prior-year quarter.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of -$0.19 per share and revenue of $371.85 million. These results would represent year-over-year changes of -107.36% and -66.9%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Novavax. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Novavax boasts a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 163, which puts it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novavax, Inc. (NVAX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).